FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring Mutations.

Unlabelled: On June 22, 2017, the Food and Drug Administration expanded indications for dabrafenib and trametinib to include treatment of patients with metastatic non-small cell lung cancer (NSCLC) harboring BRAF V600E mutations. Approval was based on results from an international, multicenter, multicohort, noncomparative, open-label trial, study BRF113928, which sequentially enrolled 93 patients who had received previous systemic treatment for advanced NSCLC (Cohort B,  = 57) or were treatment-naïve (Cohort C,  = 36). All patients received dabrafenib 150 mg orally twice daily and trametinib 2 mg orally once daily.

Mobilising a rural community to lose weight: impact evaluation of the WellingTonne Challenge.

Objective: To evaluate the impact of the WellingTonne Challenge.

Design: Before-after study.

Setting: The National Action Agenda for the prevention and control of obesity in Australia identified community action and development as a key theme.